U.S. Diversified Financial Stock News

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Six Flags Entertainment Corporation recently opened the Speedway Stunt Coaster, a family boomerang roller coaster at Six Flags México, with a grand celebration attended by hundreds of guests. The attraction highlights the company’s emphasis on family-friendly, movie-inspired experiences that broaden the park’s appeal across age groups and visit occasions. We’ll now examine how this investment in an all-ages, racing-themed coaster shapes Six Flags Entertainment’s broader investment...

If you are wondering whether Matador Resources is offering good value right now, it helps to step back from the headline price and look at what the numbers actually say about the business. The share price last closed at US$47.35, with returns of 4.7% over the past 7 days, 12.1% over 30 days, 9.2% year to date, a 14.0% decline over 1 year, a 22.7% decline over 3 years, and a 154.7% gain over 5 years. Taken together, these figures give a mixed picture of recent momentum and risk...

SkyWest (NasdaqGS:SKYW) announced multi year contract extensions with United Airlines and Delta Air Lines. The company also reported the delivery of new E175 aircraft tied to these agreements. For you as an investor, the key point is that SkyWest, a major regional airline operator, is deepening its ties with two of the largest U.S. carriers through these renewed contracts. The addition of new E175 aircraft fits within the broader regional aviation focus on fuel efficient, right sized jets...

If you are wondering whether Cohen & Steers is priced attractively today, you are not alone. This article will walk through what the current share price may be implying about value. The stock recently closed at US$62.71, with returns of a 2.4% decline over 7 days, 7.8% decline over 30 days, 1.4% decline year to date, 27.2% decline over 1 year and 6.3% decline over 3 years, while the 5-year return stands at 7.3%. Recent market attention has focused on how asset managers are being priced amid...

Carlisle Companies (CSL) has drawn fresh investor attention after releasing fourth quarter and full year 2025 results, issuing 2026 revenue guidance, and updating its capital returns through share repurchases and a newly affirmed dividend. See our latest analysis for Carlisle Companies. The latest earnings release, 2026 revenue guidance and update on buybacks and dividends arrived alongside strong share price momentum. The 7 day share price return of 18.47% and the 90 day share price return...

Nuvalent (NUVL) has drawn investor attention as a clinical stage cancer drug developer with no current revenue, a reported net loss of US$381.435 million, and a share price of US$103.59. See our latest analysis for Nuvalent. Recent trading has been mixed, with a 2.67% 1 day share price return and an 11.41% 90 day share price return. The 1 year total shareholder return of 20.90% and 3 year total shareholder return of about 3.6x indicate that longer term momentum has been much stronger than...

If you are trying to figure out whether American Bitcoin's share price really lines up with its underlying value, you are in the right place. This article is built to help you make sense of what the current price might be implying. The stock most recently closed at US$1.31, after a 13.2% decline over the last 7 days and a 28.4% decline over the last 30 days, with year to date returns at a 26.4% decline. These moves have put American Bitcoin on the radar for investors who track more volatile...

If you are wondering whether QuantumScape's current share price lines up with its long term promise, this article will walk you through how the numbers stack up. The stock closed at US$8.47 recently, with a 4.3% decline over 7 days, a 20.2% decline over 30 days, a 23.4% decline year to date, a 71.5% gain over the past year, a 3.2% gain over 3 years, and an 84.5% decline over 5 years. Recent attention on QuantumScape has been driven less by short term events like earnings and more by its...

Plains GP Holdings (PAGP) closed FY 2025 with fourth quarter revenue of US$10.6b and basic EPS of a US$0.20 loss, while trailing twelve month revenue came in at US$44.3b with basic EPS of a US$0.62 loss. The company reported quarterly revenue of US$12.4b in Q4 2024 and US$10.6b in Q4 2025, with basic EPS moving from a US$0.06 loss to a US$0.20 loss over the same period. This has set up a results season where investors are weighing volume stability against pressure on earnings. Given the mix...

SHIELD contract opens a new channel of potential work Redwire (RDW) recently secured a position on the Missile Defense Agency's SHIELD indefinite delivery indefinite quantity contract, a multi company vehicle with a US$151b ceiling and no guaranteed revenue. See our latest analysis for Redwire. Redwire's latest SHIELD contract news comes after a sharp 62.72% 90 day share price return, even though the 1 year total shareholder return is a 52.03% decline and the 3 year total shareholder return...

If you are looking at Enphase Energy and wondering whether the current share price reflects its true worth, this article will help you connect the recent moves in the stock to what the fundamentals might be saying. The shares last closed at US$49.80, with returns of 34.7% over the past week, 41.4% over the past month, and 47.6% year to date, set against a 21.6% decline over the past year and much larger falls over the last 3 and 5 years. Recent news flow around Enphase Energy has focused on...

Why MSCI’s latest earnings, buybacks and dividend move matter MSCI (MSCI) is back in the spotlight after its fourth quarter and full year 2025 results, updated share repurchase activity, and a higher cash dividend, all of which directly affect shareholder returns. For the fourth quarter, MSCI reported sales of US$822.53 million, compared with US$743.51 million a year earlier. Net income was US$284.67 million versus US$305.52 million, with diluted earnings per share from continuing operations...

Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjusted weight loss at week 28. See our latest analysis for Pfizer. The PF-3944 data lands after a busy spell for Pfizer, including better than expected Q4 2025 adjusted earnings, reaffirmed 2026 revenue guidance, a fresh Priority Review for hemophilia drug HYMPAVZI, and ongoing cost and pricing pressures such as TrumpRx agreements. The...

KKR (NYSE:KKR) has agreed to acquire Arctos Partners, moving directly into investments in professional sports franchises. The firm plans to create a new unit called KKR Solutions, with Arctos forming a key part of this expanded platform. Separately, KKR has agreed to acquire a majority stake in ST Telemedia Global Data Centres, one of Asia's largest data center operators. The ST Telemedia Global Data Centres deal is described as KKR's largest infrastructure investment in Asia Pacific. For...

Streamex Corp. recently appointed Anthony Marciano, Clinical Professor of Finance at NYU Stern and former senior Wall Street banker, as an independent director to its Board, adding deep expertise in corporate finance, mergers and acquisitions, and capital markets. Marciano’s combination of academic influence and high-level investment banking experience may reinforce Streamex’s governance credentials as it expands its tokenization and capital markets initiatives. Next, we will examine how...

Why GSBR-1290’s phase 2 progress matters for Structure Therapeutics (GPCR) Structure Therapeutics (GPCR) is back in focus as its oral obesity candidate GSBR-1290 advances through phase 2 trials. This is a key clinical stage that can materially influence sentiment around the company’s pipeline and valuation. See our latest analysis for Structure Therapeutics. At a share price of US$74.92, Structure Therapeutics has had a mixed short term pattern, with a 1 day share price return of 2.34% but a...

If you are wondering whether STERIS is priced fairly at around US$252 per share, you are not alone; many investors are asking whether the current tag matches the underlying business. The stock has had a mixed run recently, with a 4% decline over the last week, a 1.8% decline over the last month, but returns of 0.8% year to date, 14.1% over 1 year, 34.6% over 3 years and 44.3% over 5 years. Recent news coverage has focused on STERIS as a key player in healthcare equipment and services, which...

FuboTV (NYSE:FUBO) reports Q4 revenue that comes in above its own expectations. The company highlights progress on a planned Hulu Live integration to broaden content access for subscribers. Management addresses an ongoing dispute with NBCUniversal while emphasizing continuity of its service. FuboTV adopts new monetization approaches using Disney's ad platform to refine its advertising business. FuboTV operates in the crowded live TV streaming market, where viewers are trading traditional...

Hydrorich Cream launch and why Honest Company (HNST) is back on investors’ radars Honest Company (HNST) just expanded its skincare lineup with Hydrorich Cream, a new moisturizer aimed at dry and extra dry skin, and investors are asking what this means for the stock. See our latest analysis for Honest Company. Hydrorich Cream arrives at a time when Honest Company’s short term trading has been choppy, with a 7 day share price return of 7.29% decline and a 30 day share price return of 11.24%...

Exponent, Inc. recently reported fourth-quarter 2025 results showing year-on-year growth in sales and revenue, modestly higher earnings per share, and full-year 2025 revenue of US$582.01 million alongside a slightly lower annual net income of US$106.01 million. The company paired this earnings beat with guidance for high-single-digit revenue growth in 2026, an increased quarterly dividend to US$0.31 per share, and emphasis on demand tied to artificial intelligence, user research, and risk...

Wondering if Forestar Group at around US$29.27 is offering genuine value or if the easy gains are already behind it? This article walks through the key numbers so you can judge the price with more confidence. The stock has delivered returns of 12.5% over 7 days, 6.8% over 30 days, 20.4% year to date, 27.8% over 1 year and a very large 3 year gain. This naturally raises questions about how much of the good news might already be reflected in the share price. Recent price moves are set against...

If you are wondering whether Monster Beverage's current share price really reflects what you are getting for your money, you are not alone. This article is written with that question front and center. The stock last closed at US$82.54, with reported returns of 2.2% over 7 days, 6.7% over 30 days, 8.4% year to date, 77.2% over 1 year and 80.0% over 5 years. This naturally raises questions about how the present price lines up with underlying value. Recent news coverage around Monster Beverage...

Dole plc announced it will begin filing using U.S. domestic issuer forms while keeping its foreign private issuer status. The company plans to transition its filings going forward to align more closely with U.S. reporting practices. This change is intended to increase comparability with U.S. public companies and may affect index eligibility. Dole (NYSE:DOLE) is making a reporting shift that could matter if you follow U.S. equities closely. By choosing domestic issuer forms while retaining...